Non-Dystrophic Myotonia
6
0
0
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Pilot Study for the Development of an Activity and Quality of Life Questionnaire for the Follow-up of Patients With Non-dystrophic Myotonia
Contractile Properties of Hypertrofic Muscles in Patients With Non-Dystrophic Myotonia
Treatment of Myotonia - Lamotrigine Versus Namuscla
MExiletine Versus Lamotrigine in Non-Dystrophic Myotonias
Using MRI in Patients With Non-dystrophic Myotonia to Access Muscle Contractility
Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia